hemotune AG, a spin-off from ETH Zurich founded in 2017 and being accelerated by Wyss Zurich, today announced the closing of a CHF 7.25 million Series B1 for the development of HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment consortium was led by OCCIDENT with the participation of all previous investors including Zürcher Kantonalbank and joined by the new investors HEMEX, VP Venture Partners as well as a global family office and private individuals. We interviewed CEO Lukas Langegger to know more.

hemotune AG is developping a revolutionary medical device for blood purification that combines cutting-edge scientific results from biomedicine and nanotechnology. It allows specific and direct remova... Read more

Lukas Langenegger co-founded hemotune, a Venture Leader Medtech that has designed a multi-target precision-medicine blood purification treatment to restore immu...

OCCIDENT with participation of the Korean medical device company Green Cross Medical Science Corp. (GCMS), and Zürcher Kantonalbank led the investment in the ET...